Literature DB >> 2754665

Fall in antiphospholipid antibody at time of thromboocclusive episodes in systemic lupus erythematosus.

C Drenkard1, J Sánchez-Guerrero, D Alarcón-Segovia.   

Abstract

A relationship between antiphospholipid antibodies (APLA) and thromboses has been proposed in patients with systemic lupus erythematosus (SLE). In most instances, however, the thromboocclusive episodes were historic and did not coincide with the study of APLA. We studied 6 patients with SLE who, having had sequential determinations with high levels of APLA, were found to have falls in them coincident with thromboocclusive episode(s) and not attributable to treatment. Because our patients had recurrent thrombotic episodes, higher previous and subsequent titers of APLA, and other manifestations that have been similarly proposed to associate with APLA, our observations may indicate consumption of the APLA in the course of the thromboocclusive episode.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2754665

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  11 in total

Review 1.  Testing for and clinical significance of anticardiolipin antibodies.

Authors:  S W Reddel; S A Krilis
Journal:  Clin Diagn Lab Immunol       Date:  1999-11

Review 2.  Clinical and laboratory features of the catastrophic antiphospholipid syndrome.

Authors:  Ljudmila Stojanovich; Dragomir Marisavljevic; Jozef Rovensky; Aleksandra Djokovich; Darina Kozáková; Nikola Milinic
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

3.  A decrease in antiphospholipid antibodies before a thrombotic event.

Authors:  S Praprotnik; B Bozic
Journal:  Clin Rheumatol       Date:  1996-05       Impact factor: 2.980

4.  An extraordinary case of recurrent stroke, disseminated thrombosis and endocarditis.

Authors:  Liza Mariam Thomas; Niaz Ahmed Shaikh; Ranjana Pradeep
Journal:  BMJ Case Rep       Date:  2018-06-04

5.  Clinical quiz. Quiescent lupus nephritis with superimposed HUS.

Authors:  N Baqi; A Singh; S Moazani; H Ahmad; A Nicastri; A Tejani
Journal:  Pediatr Nephrol       Date:  1995-10       Impact factor: 3.714

6.  Anti-lysobisphosphatidic acid antibodies in patients with antiphospholipid syndrome and systemic lupus erythematosus.

Authors:  C Alessandri; M Bombardieri; L Di Prospero; P Conigliaro; F Conti; G Labbadia; R Misasi; M Sorice; G Valesini
Journal:  Clin Exp Immunol       Date:  2005-04       Impact factor: 4.330

7.  Neurological dysfunction and hyperactive behavior associated with antiphospholipid antibodies. A mouse model.

Authors:  L Ziporen; Y Shoenfeld; Y Levy; A D Korczyn
Journal:  J Clin Invest       Date:  1997-08-01       Impact factor: 14.808

Review 8.  Catastrophic antiphospholipid syndrome: how to diagnose a rare but highly fatal disease.

Authors:  Cassyanne L Aguiar; Doruk Erkan
Journal:  Ther Adv Musculoskelet Dis       Date:  2013-12       Impact factor: 5.346

9.  Antiphospholipid syndrome: five year follow up.

Authors:  R A Asherson; E Baguley; C Pal; G R Hughes
Journal:  Ann Rheum Dis       Date:  1991-11       Impact factor: 19.103

10.  Analysis of Thrombophilia Test Ordering Practices at an Academic Center: A Proposal for Appropriate Testing to Reduce Harm and Cost.

Authors:  Yu-Min Shen; Judy Tsai; Evelyn Taiwo; Chakri Gavva; Sean G Yates; Vivek Patel; Eugene Frenkel; Ravi Sarode
Journal:  PLoS One       Date:  2016-05-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.